|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
81,510,000 |
Market
Cap: |
1.89(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$17.69 - $45.07 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Beam Therapeutics is a biotechnology company. Co. has identified four development candidates to date: three from its ex vivo platform, with two candidates targeting hemoglobinopathies and one candidate targeting T-cell leukemia, and one from its in vivo platform targeting glycogen storage disease. BEAM-102 directly corrects the causative mutation in sickle cell disease by recreating a naturally-occurring normal human hemoglobin variant, HbG-Makassar. BEAM-201 is an anti-CD7, multiplex edited, allogeneic chimeric antigen receptor T cell development candidate for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
1,016,735 |
1,088,642 |
1,249,399 |
1,617,862 |
Total Sell Value |
$31,322,673 |
$33,197,856 |
$38,301,409 |
$55,212,492 |
Total People Sold |
6 |
6 |
6 |
6 |
Total Sell Transactions |
9 |
12 |
17 |
40 |
End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Nelsen Robert |
Director |
|
2021-03-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,921,519 |
|
- |
|
Burow Kristina |
Director |
|
2021-03-18 |
4 |
A |
$0.00 |
$0 |
D/D |
2,012 |
2,012 |
|
- |
|
Burow Kristina |
Director |
|
2021-03-18 |
4 |
D |
$0.00 |
$0 |
I/I |
(400,000) |
3,921,519 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2021-03-05 |
4 |
OE |
$0.67 |
$2,700 |
D/D |
4,030 |
19,761 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2021-01-28 |
4 |
A |
$0.00 |
$0 |
I/I |
356,673 |
713,347 |
|
- |
|
Burrell Terry-Ann |
CFO |
|
2021-01-04 |
4 |
AS |
$78.05 |
$2,044,485 |
D/D |
(25,000) |
7,309 |
|
-20% |
|
Burrell Terry-Ann |
CFO |
|
2021-01-04 |
4 |
OE |
$13.68 |
$342,000 |
D/D |
25,000 |
32,309 |
|
- |
|
Ciaramella Giuseppe |
President & CSO |
|
2020-09-30 |
4 |
OE |
$0.67 |
$2,500 |
D/D |
3,731 |
3,731 |
|
- |
|
Burrell Terry-Ann |
CFO |
|
2020-09-18 |
4 |
OE |
$13.68 |
$99,987 |
D/D |
7,309 |
7,309 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2020-08-07 |
4 |
A |
$0.00 |
$0 |
I/I |
356,674 |
356,674 |
|
- |
|
Evans John M. |
CEO |
|
2020-04-16 |
4 |
OE |
$1.03 |
$118,450 |
D/D |
115,000 |
993,257 |
|
- |
|
Green Jeremy |
10% Owner |
|
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
1,161,458 |
1,161,458 |
|
- |
|
Fmr Corp |
See Remark 1 |
|
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
6,971,912 |
6,971,912 |
|
- |
|
Burow Kristina |
Director |
|
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
8,243,039 |
4,121,519 |
|
- |
|
Bybee Clinton |
10% Owner |
|
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
8,243,039 |
4,121,519 |
|
- |
|
Fishman Mark |
Director |
|
2020-02-10 |
4 |
A |
$0.00 |
$0 |
D/D |
17,007 |
17,007 |
|
- |
|
Nelsen Robert |
Director |
|
2020-02-10 |
4 |
A |
$0.00 |
$0 |
I/I |
8,243,039 |
4,121,519 |
|
- |
|
Evans John M. |
CEOOfficer |
|
2020-02-05 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
223,000 |
|
- |
|
Evans John M. |
CEOOfficer |
|
2020-02-05 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
878,257 |
|
- |
|
169 Records found
|
|
Page 7 of 7 |
|
|